Abstract:A general, mild method for biomimetic dehydrogenative intermolecular formal allylic amidation of branched α‐olefins is developed to selectively afford substituted allylic amides by means of combined photoredox, cobalt, and Brønsted base catalysis without the need for external oxidants. The transformation features a broad substrate scope and good functional group tolerance and can be used for functionalization of structurally complex molecules. In addition the products can undergo various derivatization reactions. Allylic amide moieties are commonly encountered in natural products and are privileged structures in pharmaceuticals and agrochemicals. Moreover, because allylic amide can be to converted into an array of high‐value motifs, they have been widely employed in organic synthesis. However, the development of catalytic systems for intermolecular allylic amidation of olefins, particularly branched α‐olefins, has proven to be challenging. Here, a biomimetic, synergistic catalytic method is reported that combines photoredox, cobalt, and Brønsted base catalysis for the synthesis of substituted allylic amides from branched α‐olefins and simple imides without using oxidants. This low‐cost, operationally simple method features a broad substrate scope and excellent functional group compatibility. Moreover, it is successfully used for the functionalization of several structurally complex molecules demonstrating the method's potential utility for medicinal chemistry applications. Mechanistic studies revealed that C(sp3)─N bond formation is mediated by a nitrogen‐centered radical intermediate, which is generated via a sequence involving deprotonation and single‐electron oxidation.

Catalyst‐Controlled Regiodivergent Synthesis of Α/β‐dipeptide Derivatives Via N‐Allylic Alkylation of O‐Alkyl Hydroxamates with MBH Carbonates

Cobalt-catalyzed Branched Selective Hydroallylation of Terminal Alkynes.

Temperature-Regulated Regiodivergent Synthesis via Alkene Migratory Hydroalkylation

Nucleophile-Dependent Z/ E- and Regioselectivity in the Palladium-Catalyzed Asymmetric Allylic C-H Alkylation of 1,4-Dienes.

Cobalt-Catalyzed Markovnikov Selective Sequential Hydrogenation/Hydrohydrazidation of Aliphatic Terminal Alkynes

Cobalt-Catalyzed Markovnikov-Type Selective Hydroboration of Terminal Alkynes

Palladium-catalyzed base- and solvent-controlled chemoselective allylation of amino acids with allylic carbonates

(E)-Α,β-unsaturated Amides from Tertiary Amines, Olefins and CO Via Pd/Cu-catalyzed Aerobic Oxidative N-dealkylation

Stereodivergent access to non-natural α-amino acids via enantio- and Z / E -selective catalysis

Hydrogen Source Tuned Regiodivergent Asymmetric Hydroalkylations of 2‐Substituted 1,3‐Dienes with Aldehydes by Cobalt‐Catalysis

Regioselectivity Switch of α-Amino Acid-Derived Esters and MBH Carbonates for the Synthesis of Allyl-Substituted Azlactones

Palladium-Catalyzed Regio- and Stereoselective Cross-Coupling of Vinylethylene Carbonates with Ketimine Esters to Generate ( Z )-Tri- and Tetra-substituted Allylic Amino Acid Derivatives.

Ligand-Controlled NiH-Catalyzed Regiodivergent and Enantioselective Hydroamination of Alkenyl Amides

Ligand-Controlled Cobalt-Catalyzed Regiodivergent Alkyne Hydroalkylation.

Regio- and stereoselective syntheses of chiral alpha-quaternary (Z)-trisubstituted allylic amino acids via synergistic Pd/Cu catalysis

Hydrogen-Evolution Allylic C(sp 3 )–H Alkylation with Protic C(sp 3 )–H Bonds via Triplet Synergistic Brønsted Base/Cobalt/Photoredox Catalysis

De Novo Synthesis of α-Ketoamides via Pd/TBD Synergistic Catalysis

Asymmetric Synthesis of 3-Hydroxyl-2-alkanones Via Tandem Organocatalytic Aminoxylation of Aldehydes and Chemoselective Diazomethane Homologation

Biomimetic Dehydrogenative Intermolecular Formal Allylic Amidation of Branched α‐Olefins

Enantioselective Three‐Component α‐Allylic Alkylation of α‐Amino Esters by Synergistic Photoinduced Pd/Carbonyl Catalysis

1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.